Home / Going-concern warnings / TriSalus Life Sciences, Inc.
Filed 2025-04-15 路 Form 10-K 路 Accession 0001826667-25-000030 micro
Price before filing: $5.55 (2025-04-14 close, split/dividend-adjusted)
Market cap at flag: $181.6M (2025-04-15) 路 Latest: $211.6M (2026-10-16)
| Window | TLSI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -7.9% | +9.5% | -17.5% | 2025-05-15 |
| 90 days | -10.3% | +16.2% | -26.5% | 2025-07-14 |
| 180 days | -17.3% | +23.7% | -41.0% | 2025-10-13 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 3 insiders bought $423K (8 purchases)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-01-27 | Murphy Sean Chief Manuf, Strategy&Bus Dev., Director | Purchase | 15,000 | $5.31 | $80K | no | Form 4 |
| 2025-01-27 | Szela Mary T CEO AND PRESIDENT, Director | Purchase | 4,826 | $5.42 | $26K | no | Form 4 |
| 2025-01-27 | Young James Emmett Chief Financial Officer | Purchase | 24,000 | $5.40 | $130K | no | Form 4 |
| 2025-01-28 | Murphy Sean Chief Manuf, Strategy&Bus Dev., Director | Purchase | 15,000 | $5.17 | $78K | no | Form 4 |
| 2025-01-28 | Szela Mary T CEO AND PRESIDENT, Director | Purchase | 4,716 | $5.12 | $24K | no | Form 4 |
| 2025-01-29 | Szela Mary T CEO AND PRESIDENT, Director | Purchase | 5,030 | $5.03 | $25K | no | Form 4 |
| 2025-01-30 | Szela Mary T CEO AND PRESIDENT, Director | Purchase | 5,010 | $5.28 | $26K | no | Form 4 |
| 2025-02-05 | Young James Emmett Chief Financial Officer | Purchase | 6,000 | $5.65 | $34K | no | Form 4 |
| 2025-04-15: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-01-15 to 2025-05-15. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"These matters raise substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: Grant Thornton LLP
Source: independent auditor report in Form 10-K (period 2024-12-31)
Why this score: in auditor's report
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.